Lumito AB publishes Quarterly Report 2, 2023
First half of the year 1 January – 30 June 2023 Net sales amounted to KSEK 0 (0). Result after taxes amounted to KSEK -14,668 (-13,610). Basic and diluted earnings per share amounted to SEK -0.07 (-0.09). Cash flow from operating activities after change in working capital amounted to KSEK -13,734 (-14,636). Cash and cash […]
The Promising Results from Lumito’s First International Pilot Study Were Presented at Liverpool Pathology 2023
The results from Lumito's first international pilot study show that it is possible to detect the deposition of immunoglobulin and complement in renal tissue using Lumito's technology. The result confirms the expectations that the study was based around and demonstrates that Lumito's technology has the potential to be established in renal diagnostics. In May, Lumito's […]
Lumito attends the 19th European Congress on Digital Pathology in Budapest
Lumito is attending the 19th European Congress on Digital Pathology in Budapest, June 14th – 17th, 2023. Lumito's Project Manager, Krzysztof Krawczyk, is present with the company's CTO, Andreas Johansson. Krzysztof also gives a poster presentation. See attached picture from the first day. For further information, please contact: Mattias Lundin, CEO LumitoE-mail: ml@lumito.sePh: +46 76 868 […]
Lumito launches new website
Lumito has now launched a new website. The website is designed to better reflect Lumito's ongoing commercialisation phase, with a special focus on the SCIZYS product ahead of the upcoming product launch. Visit our new website here! For further information, please contact: Mattias Lundin, CEO LumitoE-mail: ml@lumito.sePh: +46 76 868 45 09 Lumito Lumito specialises in medical […]
EMC testing at an external company in Germany
Yesterday, EMC testing (electromagnetic compatibility testing) of Lumito's product, SCIZYS, began with an external independent testing company in Germany to obtain an external assessment that ensures the product meets all relevant requirements. The company has prepared well with Optronic Partner pr for the independent EMC test and is now ready. The EMC testing is a […]
Presentation of results from a pilot study using Lumito’s imaging technology
In December 2022, the scientific article "Extracellular galectin 4 drives immune evasion and promotes T-cell apoptosis in pancreatic cancer" was published in Cancer Immunology Research. The lead author of the published article, Tommy Lidström, was at Lumito in mid-February to present the results as part of Lumito's first exclusive presentation held for potential end customers […]
Updated analysis by Mangold Insight
Today, Mangold Insight published an updated company analysis of Lumito. The company analysis in a commissioned analysis and is available here, but can also be accessed from Lumito’s website here. Please note that the company analysis is in Swedish. For further information, please contact: Mattias Lundin, CEO Lumito E-mail: ml@lumito.se Ph: +46 76 868 45 09 […]
Exhibiting at EACR Congress in Torino and Nordic Oncology Forum in Stockholm in June 2023
Continuing the company’s marketing work towards commercialization by igniting interest and awareness in potential customers and collaborators, Lumito will be exhibiting at the European Association for Cancer Research (EACR) 2023 in Torino, Italy 12-15 of June, as well as Nordic Oncology Forum in Stockholm 26-27 of June. “We look forward to showcasing our product and […]
Live demonstration of Lumito’s scanner confirmed problem-solving capabilities
We finally got to show our product, SCIZYS by Lumito, during a live demonstration where tissue images were scanned in Lumito's laboratory under the supervision of around ten researchers and pathologists from the Malmö/Lund area. The visitors saw the added value of our product and confirmed the problem that Lumito could potentially solve. Tommy Lidström, […]
Planning for the next strategic step after Europe – the US tissue diagnostics research market
Following the launch of SCIZYS, Lumito's solution for research laboratories operating in tissue diagnostics in Sweden, followed by the Nordic countries and the rest of Europe, the next strategic step is now being planned, a launch in the world's largest research market, the US. This growing market is estimated to be worth approximately USD 733 […]
